Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ramalingam

Showing results (331-340 of 502) with videos related to

Pageof 51
Sort By:
Nucleic Acids Research|March 10, 2018
Overexpression of the base excision repair NTHL1 glycosylase causes genomic instability and early cellular hallmarks of cancerKristin L Limpose, Kelly S Trego, Zhentian Li, et al.
Clinical Lung Cancer|April 5, 2017
Stereotactic Body Radiotherapy for Early-stage Non-small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center AnalysisRichard J Cassidy, Pretesh R Patel, Xinyan Zhang, et al.
Cell Reports|December 14, 2022
EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancerJiHoon Kang, Jaemoo Chun, Jung Seok Hwang, et al.
Clinical Lung Cancer|July 31, 2016
Overview of Thoracic Oncology Trials in Cooperative Groups Around the GlobeAmeen Abdulla Salahudeen, Manali I Patel, Paul Baas, et al.
The Journal of Clinical Investigation|June 16, 2022
MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancerDan Yan, Justus M Huelse, Dmitri Kireev, et al.
JAMA Oncology|December 16, 2016
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic ReviewConor E Steuer, Madhusmita Behera, Vinicius Ernani, et al.
The Journal of Molecular Diagnostics : JMD|November 19, 2023
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro DiagnosticJhanelle E Gray, Ji-Youn Han, Aino Telaranta-Keerie, et al.
Cancer|March 3, 2011
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignanciesJohn Kauh, Chantal Chanel-Vos, Daniel Escuin, et al.
The Oncologist|January 17, 2020
Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database AnalysisMadhusmita Behera, Conor E Steuer, Yuan Liu, et al.
Nature Communications|February 27, 2023
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancerJuliann Chmielecki, Jhanelle E Gray, Ying Cheng, et al.
Pageof 51

Showing results (331-340 of 502) with videos related to

Sort By:
Pageof 51
Nucleic Acids Research|March 10, 2018
Overexpression of the base excision repair NTHL1 glycosylase causes genomic instability and early cellular hallmarks of cancerKristin L Limpose, Kelly S Trego, Zhentian Li, et al.
Clinical Lung Cancer|April 5, 2017
Stereotactic Body Radiotherapy for Early-stage Non-small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center AnalysisRichard J Cassidy, Pretesh R Patel, Xinyan Zhang, et al.
Cell Reports|December 14, 2022
EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancerJiHoon Kang, Jaemoo Chun, Jung Seok Hwang, et al.
Clinical Lung Cancer|July 31, 2016
Overview of Thoracic Oncology Trials in Cooperative Groups Around the GlobeAmeen Abdulla Salahudeen, Manali I Patel, Paul Baas, et al.
The Journal of Clinical Investigation|June 16, 2022
MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancerDan Yan, Justus M Huelse, Dmitri Kireev, et al.
JAMA Oncology|December 16, 2016
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic ReviewConor E Steuer, Madhusmita Behera, Vinicius Ernani, et al.
The Journal of Molecular Diagnostics : JMD|November 19, 2023
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro DiagnosticJhanelle E Gray, Ji-Youn Han, Aino Telaranta-Keerie, et al.
Cancer|March 3, 2011
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignanciesJohn Kauh, Chantal Chanel-Vos, Daniel Escuin, et al.
The Oncologist|January 17, 2020
Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database AnalysisMadhusmita Behera, Conor E Steuer, Yuan Liu, et al.
Nature Communications|February 27, 2023
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancerJuliann Chmielecki, Jhanelle E Gray, Ying Cheng, et al.
Pageof 51